Ligne de temps
Nadira Frescaline
Post-doctorant(e)
22 févr. 2023
publication
Complete Genome Sequences of Bioluminescent Staphylococcus aureus Strains Xen31 and Xen36, Derived from Two Clinical Isolates.
Lire plus09 sept. 2022
project
- NOVOPLASM – Un axe NOVateur pOur cicatriser les brûlures sévères infectées par l’application de PLASMa froid
Lire plus01 janv. 2022
publication
Danger signals in traumatic hemorrhagic shock and new lines for clinical applications.
Lire plus16 juin 2021
publication
Cold Atmospheric Plasma Promotes Killing of Staphylococcus aureus by Macrophages.
Lire plus01 déc. 2020
publication
Physical plasma therapy accelerates wound re-epithelialisation and enhances extracellular matrix formation in cutaneous skin grafts.
Lire plus28 août 2020
08 août 2020
01 nov. 2019
publication
Cold atmospheric plasma modulates endothelial nitric oxide synthase signalling and enhances burn wound neovascularisation.
Lire plus01 janv. 2018
publication
Mesenchymal Stromal Cells Based Therapy in Systemic Sclerosis: Rational and Challenges.
Lire plus01 déc. 2016
publication
Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis.
Lire plus01 déc. 2016
publication
Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis.
Lire plus05 juil. 2016
21 mars 2015
publication
Identification of NF-κB and PLCL2 as new susceptibility genes and highlights on a potential role of IRF8 through interferon signature modulation in systemic sclerosis.
Lire plus01 janv. 2015
publication
Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis.
Lire plus01 nov. 2014
publication
The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis.
Lire plus01 févr. 2014
publication
Attenuation of flightless I improves wound healing and enhances angiogenesis in a murine model of type 1 diabetes.
Lire plus01 oct. 2013
publication
Venous ulceration contaminated by multi-resistant organisms: larval therapy and debridement.
Lire plus01 avr. 2013
publication
Topically applied flightless I neutralizing antibodies improve healing of blistered skin in a murine model of epidermolysis bullosa acquisita.
Lire plus01 janv. 2013
publication
The influence of Flightless I on Toll-like-receptor-mediated inflammation in a murine model of diabetic wound healing.
Lire plus01 nov. 2012
publication
Lysosomal secretion of Flightless I upon injury has the potential to alter inflammation.
Lire plus15 sept. 2012
publication
Flightless, secreted through a late endosome/lysosome pathway, binds LPS and dampens cytokine secretion.
Lire plus12 sept. 2012
publication
Cytoskeletal protein Flightless (Flii) is elevated in chronic and acute human wounds and wound fluid: neutralizing its activity in chronic but not acute wound fluid improves cellular proliferation.
Lire plus01 août 2009
publication